NCT00648167View on ClinicalTrials.gov

A Safety and Tolerability Study of Zerenex (Ferric Citrate) in Patients With End-Stage Renal Disease (ESRD)

PHASE2CompletedINTERVENTIONAL
Enrollment

55

Participants

Timeline

Start Date

March 31, 2008

Primary Completion Date

January 31, 2009

Study Completion Date

January 31, 2009

Conditions
HyperphosphatemiaEnd-stage Renal Disease
Interventions
DRUG

ferric citrate

ferric citrate will be provided as a 375mg capsule. Dosing and frequency are dependent on patient's serum phosphorus levels. Dosing will occur over the 28-day study.

Trial Locations (1)

37232

Vanderbilt University Medical Center, Nashville

Sponsors
All Listed Sponsors
collaborator

Collaborative Study Group (CSG)

NETWORK

lead

Keryx Biopharmaceuticals

INDUSTRY

NCT00648167 - A Safety and Tolerability Study of Zerenex (Ferric Citrate) in Patients With End-Stage Renal Disease (ESRD) | Biotech Hunter | Biotech Hunter